股本结构
单位：万股
| 公告日期 | 2024-02-13 | 2023-11-13 | 2023-09-21 | 2023-08-10 | 2023-07-25 | 2022-11-10 |
|---|---|---|---|---|---|---|
| 证券总股本 | 259.24 | 257.24 | 254.74 | 206.38 | 164.60 | 2798.12 |
| 普通股本 | 259.24 | 257.24 | 254.74 | 206.38 | 164.60 | 2798.12 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2023-12-31 | 2023-11-07 | 2023-08-16 | 2023-08-11 | 2023-07-26 | 2022-11-09 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
，当前存托凭证比例为：1
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-02-13 | 259.24 | 未披露 |
更多>>
From September 30, 2023 to December 31, 2023
Exercise of pre-funded warrants
Exercise of Series 2 warrants
|
2023-12-31 |
| 2023-11-13 | 257.24 | 未披露 | 定期报告 | 2023-11-07 |
| 2023-09-21 | 254.74 | 未披露 | 定期报告 | 2023-08-16 |
| 2023-08-10 | 206.38 | 未披露 |
更多>>
Common stock offered 417,815 shares by the company
|
2023-08-11 |
| 2023-07-25 | 164.60 | 未披露 |
更多>>
Benitec Biopharma Inc. announced that it will effect a 1-for-17 reverse stock split of its common stock, par value $0.0001 per share, that will become effective on July 26, 2023, at 12:01 a.m., Eastern Time.
|
2023-07-26 |
| 2022-11-10 | 2798.12 | 未披露 | 定期报告 | 2022-11-09 |
| 2022-09-14 | 2580.95 | 未披露 |
更多>>
From June 30, 2022 to September 15, 2022
Issuance of common stock, pre-funded warrants, and common warrants sold for cash, net of offering costs of $1,869
|
2022-09-15 |
| 2021-09-20 | 817.17 | 未披露 |
更多>>
From June 30, 2020 to June 30, 2021
Common stock sold for cash, net of offering costs of $3,228
Exercise of pre-funded warrants
|
2021-06-30 |
| 2021-04-30 | 785.44 | 未披露 |
更多>>
1.Common stock offered by the company 3,036,366 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 4,818,050 shares of common stock outstanding at April 26, 2021.
|
2021-04-30 |
| 2021-05-12 | 481.81 | 未披露 |
更多>>
From December 31, 2020 to Feburary 17, 2021
Exercise of pre-funded warrants
|
2021-02-17 |
| 2021-02-09 | 454.05 | 未披露 |
更多>>
From September 30, 2020 to December 31,2020
Issuance of common stock and pre-funded warrants sold for cash, net of issuance costs of $1,643
Exercise of pre-funded warrants
|
2020-12-31 |
| 2020-10-22 | 440.55 | 未披露 | 定期报告 | 2020-10-15 |
| 2020-10-06 | 433.42 | 未披露 |
更多>>
1.Common stock offered by the company 2,666,644 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 1,108,374 shares of common stock outstanding at September 28, 2020.
|
2020-10-06 |
| 2020-09-23 | 110.84 | 未披露 |
更多>>
From June 30, 2019 to June 30, 2020
Common stock sold for cash, net of offering costs of $240
Issuance and exercise of pre-funded warrants, net of transaction costs of $240
Cashless exercise of purchase warrants
|
2020-06-30 |
| 2020-04-15 | 21419.14 | 未披露 | 定期报告 | 2020-04-15 |
| 2020-02-26 | 32128.70 | 未披露 | 定期报告 | 2019-12-31 |
| 2019-12-09 | 31302.94 | 未披露 | 定期报告 | 2019-09-30 |
| 2018-10-30 | 25702.94 | 未披露 |
更多>>
from June 30, 2017 to June 30, 2018
Issue of shares Highbridge
Issue of shares Nant Capital
Issue of shares Entitlement offer
|
2018-06-30 |
| 2018-05-04 | 22058.68 | 未披露 | 定期报告 | 2018-05-04 |
| 2017-10-23 | 20514.27 | 未披露 |
更多>>
from July 1,2016 to June 30,2017
Issue of shares Nant Capital
Conversion of Warrants
|
2017-06-30 |
| 2017-06-01 | 20514.07 | 未披露 | 定期报告 | 2017-03-31 |
| 2016-11-16 | 14652.91 | 未披露 | 定期报告 | 2016-10-21 |
| 2015-10-14 | 14652.91 | 未披露 | 定期报告 | 2015-10-13 |
| 2015-08-18 | 14588.18 | 未披露 | 定期报告 | 2015-08-18 |
From September 30, 2023 to December 31, 2023
Exercise of pre-funded warrants
Exercise of Series 2 warrants
Common stock offered 417,815 shares by the company
Benitec Biopharma Inc. announced that it will effect a 1-for-17 reverse stock split of its common stock, par value $0.0001 per share, that will become effective on July 26, 2023, at 12:01 a.m., Eastern Time.
From June 30, 2022 to September 15, 2022
Issuance of common stock, pre-funded warrants, and common warrants sold for cash, net of offering costs of $1,869
From June 30, 2020 to June 30, 2021
Common stock sold for cash, net of offering costs of $3,228
Exercise of pre-funded warrants
1.Common stock offered by the company 3,036,366 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 4,818,050 shares of common stock outstanding at April 26, 2021.
From December 31, 2020 to Feburary 17, 2021
Exercise of pre-funded warrants
From September 30, 2020 to December 31,2020
Issuance of common stock and pre-funded warrants sold for cash, net of issuance costs of $1,643
Exercise of pre-funded warrants
1.Common stock offered by the company 2,666,644 shares.
2.The number of shares of common stock to be outstanding after this offering is based on 1,108,374 shares of common stock outstanding at September 28, 2020.
From June 30, 2019 to June 30, 2020
Common stock sold for cash, net of offering costs of $240
Issuance and exercise of pre-funded warrants, net of transaction costs of $240
Cashless exercise of purchase warrants
from June 30, 2017 to June 30, 2018
Issue of shares Highbridge
Issue of shares Nant Capital
Issue of shares Entitlement offer
from July 1,2016 to June 30,2017
Issue of shares Nant Capital
Conversion of Warrants